Lunai Bioworks launches chemical defence consortium for US countermeasure programmes
Lunai Bioworks has announced the formation of a national consortium designed to accelerate the discovery and development of chemical countermeasures for emerging battlefield and terrorism threats.
Announced in a press release on Thursday 19 March, The Pathfinder Consortium will be "a national academic–industry alliance designed to consolidate historically siloed US chemical warfare preparedness resources into a unified, execution-ready infrastructure capable of accelerating medical countermeasure development to approximately three years".
"For decades, America's chemical defence capabilities have existed in fragmented silos: academic toxicology labs, military research units, federal agencies, and biotech innovators operating independently," Lunai Bioworks wrote. "Pathfinder integrates these capabilities into a coordinated framework engineered for speed, capital efficiency and national readiness."
Three-year regulatory pathway
The Pathfinder Consortium will follow an accelerated three-year regulatory pathway rather than a 10-year drug timeline. The new model will be structured to demonstrate efficacy in yeast and cell-based systems, validate therapeutic effects in zebrafish models recognised by the US Food and Drug Administration, complete two confirmatory animal studies and conduct a 50-person phase one safety study. The full process is expected to be completed in 36 months.
David Weinstein, CEO of Lunai Bioworks, said: "Chemical defence cannot operate on a decade-long pharmaceutical clock. The regulatory framework allows for speed, and Pathfinder is designed to execute within that accelerated pathway."
"Pathfinder represents a strategic response, a scalable national platform positioned for what the company envisions as a potential 'Warp Speed 2' era of chemical preparedness," the company wrote in the press release.
The consortium will target US government countermeasure procurement programmes typically ranging between $400 million and $1.2 billion per programme.
Strategic and financial significance
By mobilising and organising national capabilities, Pathfinder positions BioSymetrics to access non-dilutive funding sources to compete for BARDA, DoD, and Homeland Security programmes, pursue large-scale federal procurement contracts, monetise repurposed compounds through rapid deployment pathways, and diversify revenue beyond traditional biotech development cycles.
The Consortium leverages BioSymetrics' proprietary AI-enabled phenotypic platform, integrating machine learning analytics with high-throughput vertebrate screening to rapidly identify toxicologic signatures and therapeutic leads.
"Lunai Bioworks is an AI-enabled biotechnology company advancing rapid in vivo phenotypic drug discovery across CNS and biodefence applications," the company writes of themselves. "By integrating high-throughput vertebrate screening with machine learning analytics, Lunai seeks to accelerate therapeutic discovery while reducing cost, time and capital intensity."
